Highly effective antibodies identified, may lead to passive COVID-19 vaccine


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Highly effective antibodies identified, may lead to passive COVID-19 vaccine
Unlike in active vaccination, passive vaccination involves the administration of ready-made antibodies, which are degraded after some time.

Scientists have identified highly effective antibodies against the novel coronavirus, which they say can lead to the development of a passive vaccination for COVID-19.

Unlike inactive vaccination, passive vaccination involves the administration of ready-made antibodies, which are degraded after some time.

However, the effect of a passive vaccination is almost immediate, whereas with an active vaccination it has to build up first, the researchers said.

The research, published in the journal Cell, also shows that some SARS-CoV-2 antibodies bind to tissue samples from various organs, which could potentially trigger undesired side effects.

The scientists at the German Center for Neurodegenerative Diseases (DZNE) and Charite - Universitatsmedizin Berlin isolated almost 600 different antibodies from the blood of individuals who had overcome COVID-19, the disease triggered by SARS-CoV-2.

Using laboratory tests, they were able to narrow this number down to a few antibodies that were particularly effective at binding to the virus.

The researchers then produced these antibodies artificially using cell cultures.

The so-called neutralizing antibodies bind to the virus, as crystallographic analysis reveals, and thus prevent the pathogen from entering cells and reproducing, they said.

Also, virus recognition by antibodies helps immune cells to eliminate the pathogen. Studies in hamsters -- which, like humans, are susceptible to infection by SARS-CoV-2 -- confirmed the high efficacy of the selected antibodies.

"If the antibodies were given after infection, the hamsters developed mild disease symptoms at most. If the antibodies were applied preventively -- before infection -- the animals did not get sick," said Jakob Kreye, coordinator of the research project.

The researchers noted that treating infectious diseases with antibodies has a long history.

For COVID-19, this approach is also being investigated through the administration of plasma-derived from the blood of recovered patients. With the plasma, antibodies of donors are transferred, they said.

"Ideally, the most effective antibody is produced in a controlled manner on an industrial scale and in constant quality. This is the goal we are pursuing," said Momsen Reincke, first author of the research.

"Three of our antibodies are particularly promising for clinical development," explained Harald Pruss, a research group leader at the DZNE and also a senior physician at Charite - Universitatsmedizin Berlin.

"Using these antibodies, we have started to develop a passive vaccination against SARS-CoV-2," Pruss said.

In addition to the treatment of patients, preventive protection of healthy individuals who have had contact with infected persons is also a potential application, the researchers said.

How long the protection lasts will have to be investigated in clinical studies, they said.

"This is because, unlike in active vaccination, passive vaccination involves the administration of ready-made antibodies, which are degraded after some time," Pruss said. In general, the protection provided by a passive vaccination is less persistent than that provided by an active vaccination, the researchers said.

However, the effect of a passive vaccination is almost immediate, whereas with an active vaccination it has to build up first, they said.

"It would be best if both options were available so that a flexible response could be made depending on the situation," Pruss added.

Tags : #COVID-19 #Passive #Vaccine #Antibodies

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026